PKM2 phosphorylation involves in aggressive breast cancer cell phenotypes, and PKM2 phosphorylation at Ser37 functions as an effective therapeutic target for triple-negative breast cancer treatment (Apostolidi et al., 2021). The gene discussed is PKM; the disease is breast cancer.